ORIC® Pharmaceuticals Announces Three Presentations at the European Society for Medical Oncology (ESMO) Congress 2026

Rhea-AI Summary

ORIC Pharmaceuticals (Nasdaq: ORIC) will feature three poster presentations at the ESMO Congress 2026 in Madrid, Spain, from October 23-27, 2026. The presentations cover enozertinib (ORIC-114) in treatment-naive metastatic NSCLC with EGFR atypical mutations and two posters on rinzimetostat in mCRPC.

The rinzimetostat presentations include a global Phase 3 Himalayas-1 trial-in-progress poster in patients previously treated with abiraterone and an ePoster on preclinical and patient sample data showing effects on luminal fate, AR signaling, and lineage plasticity. Full abstracts will be available on the ESMO website on October 19, 2026.

News Market Reaction – ORIC

-2.89%

6 alerts

-2.89% News Effect

+16.5% Peak Tracked

-4.6% Trough Tracked

-$33M Valuation Impact

$1.11B Market Cap

0.5x Rel. Volume

On the day this news was published, ORIC declined 2.89%, reflecting a moderate negative market reaction. Argus tracked a peak move of +16.5% during that session. Argus tracked a trough of -4.6% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $33M from the company's valuation, bringing the market cap to $1.11B at that time.

Data tracked by StockTitan Argus on the day of publication.

Market Context

Recent ORIC news reactions ranged from -6.27% to +5.59% across the supplied history. This record add...

Analysis

Recent ORIC news reactions ranged from -6.27% to +5.59% across the supplied history. This record adds event-specific context to the ESMO presentation notice; moderate short positioning and Net Selling insider activity are risks to monitor.

Key Figures

Poster presentations: 3 presentations Enozertinib trial phase: Phase 1b Rinzimetostat trial phase: Phase 3 +2 more

5 metrics

Poster presentations 3 presentations ESMO Congress 2026

Enozertinib trial phase Phase 1b First-line EGFR atypical NSCLC

Rinzimetostat trial phase Phase 3 Himalayas-1 in mCRPC previously treated with abiraterone

Congress dates October 23-27, 2026 ESMO Congress in Madrid, Spain

Abstract availability October 19, 2026 Full abstracts available through the ESMO Congress website

Historical Context

5 past events · Latest: Jul 14 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jul 14	Phase 3 trial initiation	Positive	+5.6%	Himalayas-1 initiation and Bayer collaboration for darolutamide supply
Jul 02	Inducement equity grants	Neutral	-6.3%	Equity awards granted to three newly hired non-executive employees
Jun 05	Inducement equity grants	Neutral	+0.7%	Equity awards granted to two newly hired non-executive employees
May 27	Investor conference participation	Neutral	-1.5%	Management scheduled fireside chats at two June healthcare conferences
May 04	Quarterly earnings report	Neutral	-0.6%	Q1 results included cash resources and operational updates for oncology programs

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The prior trial-initiation announcement rose 5.59%, while four other recent announcements posted reactions ranging from -6.27% to +0.67%.

Key Terms

nsclc, mcrpc, prc2 inhibitor, ar signaling

4 terms

nsclc medical

"first-line EGFR atypical NSCLC"

NSCLC stands for non-small cell lung cancer, which is the most common type of lung cancer. It develops in the lungs and can spread to other parts of the body, making it serious but often treatable if caught early. Understanding NSCLC helps people recognize the importance of lung health and early detection.

mcrpc medical

"ongoing Himalayas-1 Phase 3 study in patients with mCRPC"

mCRPC stands for metastatic castration‑resistant prostate cancer, a form of prostate cancer that has spread beyond the prostate and keeps progressing despite treatments that lower male hormones. It matters to investors because this stage is harder to treat, drives demand for new therapies, and often involves large, expensive clinical trials and regulatory decisions that can strongly influence a drug maker’s future revenue and stock value—think of it as a stubborn problem that creates both medical need and commercial opportunity.

prc2 inhibitor medical

"Rinzimetostat, an Allosteric PRC2 Inhibitor Combined With Darolutamide"

A PRC2 inhibitor is a drug that blocks the Polycomb Repressive Complex 2, a cellular “off switch” that silences genes by tightening how DNA is packaged; stopping that switch can reawaken genes that control cell growth and behavior. For investors, these inhibitors matter because they are being developed as targeted cancer and disease therapies—successful candidates can deliver clinical benefit and commercial value, while also carrying typical drug-development and regulatory risks.

ar signaling medical

"Enhances Luminal Fate and AR Signaling While Restricting Lineage Plasticity"

Androgen receptor (AR) signaling is the biological process by which hormones like testosterone bind to the androgen receptor inside cells and change which genes are turned on or off, altering cell growth and behavior. Think of the receptor as a light switch that a hormone flips to change a room’s activity; disruption or blocking of that switch is a key target for drugs in diseases driven by androgens. Investors track AR signaling because changes in this pathway, or drugs that affect it, can strongly influence clinical trial outcomes, regulatory decisions, and the commercial value of therapies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Enozertinib poster presentation to highlight data from an ongoing Phase 1b trial in first-line EGFR atypical NSCLC

Rinzimetostat trial-in-progress poster presentation to highlight the ongoing Himalayas-1 Phase 3 study design in patients with mCRPC previously treated with abiraterone

Rinzimetostat ePoster to highlight data supporting its potential to enhance AR signaling and restrict lineage plasticity in mCRPC

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, July 20, 2026 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing and commercializing treatments that address mechanisms of therapeutic resistance, today announced three poster presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.

Poster presentation details:

Title:	Enozertinib (ORIC-114), a Brain Penetrant, Highly Selective EGFR Inhibitor, in Treatment-Naive Metastatic NSCLC with EGFR Atypical Mutations
Presentation Number:	2627P
Session Date & Time:	Monday, October 26, 2026; 12:00 – 12:45 p.m. CET
Session Title:	Metastatic NSCLC
Title:	Rinzimetostat, an Allosteric PRC2 Inhibitor Combined With Darolutamide: A Global Phase 3 Study in mCRPC Patients Previously Treated With Abiraterone Acetate (Himalayas-1)
Presentation Number:	2303TiP
Session Date & Time:	Friday, October 23, 2026; 3:15 – 4:00 p.m. CEST
Session Title:	Metastatic Prostate Cancer
Title:	Rinzimetostat, a Next-Generation PRC2 Inhibitor, Enhances Luminal Fate and AR Signaling While Restricting Lineage Plasticity in Preclinical Models and Demonstrates Mechanistic Proof-of-Concept in Samples From Patients with mCRPC
Presentation Number:	1128eP
Session Title:	Developmental Therapeutics

Full abstracts will be available for public viewing via the ESMO Congress website on October 19, 2026.

About ORIC Pharmaceuticals, Inc.
ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) rinzimetostat, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and (2) enozertinib, a brain-penetrant inhibitor targeting EGFR exon 20 insertion and EGFR atypical mutations, being developed for NSCLC. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on X or LinkedIn.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

FAQ

What ESMO Congress 2026 presentations will ORIC (NASDAQ: ORIC) give on enozertinib?

ORIC will present a poster on enozertinib (ORIC-114) in treatment-naive metastatic NSCLC with EGFR atypical mutations. According to ORIC, this Phase 1b data will be shown in the Metastatic NSCLC session on October 26, 2026, presentation number 2627P.

What is the Himalayas-1 Phase 3 study of rinzimetostat in mCRPC presented by ORIC (ORIC)?

Himalayas-1 is a global Phase 3 trial of rinzimetostat, an allosteric PRC2 inhibitor, combined with darolutamide in mCRPC patients previously treated with abiraterone. According to ORIC, a trial-in-progress poster (2303TiP) will be presented October 23, 2026, in the Metastatic Prostate Cancer session.

When and where is ORIC presenting rinzimetostat mechanistic data in mCRPC at ESMO 2026?

ORIC will present an ePoster on rinzimetostat mechanistic proof-of-concept in mCRPC in the Developmental Therapeutics session. According to ORIC, this poster (1128eP) highlights enhanced luminal fate, increased AR signaling, and restricted lineage plasticity in preclinical models and patient samples.

What are the dates and location of ORIC’s ESMO Congress 2026 presentations (ticker ORIC)?

ORIC’s posters will be presented during the ESMO Congress 2026, held October 23-27, 2026, in Madrid, Spain. According to ORIC, individual sessions occur on October 23 and October 26, 2026, in disease-focused tracks.

When will abstracts for ORIC (ORIC) ESMO 2026 presentations become publicly available?

Abstracts for ORIC’s ESMO Congress 2026 presentations will be accessible on the ESMO Congress website starting October 19, 2026. According to ORIC, this includes the enozertinib Phase 1b poster and both rinzimetostat posters in mCRPC.

Which cancer types are targeted in ORIC’s ESMO 2026 presentations on enozertinib and rinzimetostat (ORIC)?

ORIC’s ESMO 2026 presentations focus on metastatic NSCLC with EGFR atypical mutations and metastatic castration-resistant prostate cancer. According to ORIC, enozertinib addresses EGFR-mutant NSCLC, while rinzimetostat studies involve mCRPC patients, including those previously treated with abiraterone.